2022
Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance
Hlady RA, Zhao X, Khoury L, Luna A, Pham K, Wu Q, Lee J, Pyrsopoulos NT, Liu C, Robertson KD. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance. Hepatology 2022, 75: 983-996. PMID: 34387871, PMCID: PMC9416882, DOI: 10.1002/hep.32111.Peer-Reviewed Original ResearchConceptsDNA methylationHistone modificationsWide DNA methylationAberrant DNA methylationGene expression analysisDNA methyltransferase inhibitorOpen chromatinEpigenetic mechanismsEpigenetic targetsHuman patient samplesEpigenetic changesEpigenomeMethyltransferase inhibitorTargetable vulnerabilitiesMethylationHCC cell linesImmortalized hepatocytesCell linesFunctional effectsChronic HCV infectionChromatinHCV infectionImmune responsePatient samplesSynergizes
2017
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson DR, Robertson K, Ostrov D, Rameshwar P, Xia CQ, Liu C. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Molecular Therapy 2017, 25: 2299-2308. PMID: 28865999, PMCID: PMC5628867, DOI: 10.1016/j.ymthe.2017.08.005.Peer-Reviewed Original ResearchConceptsC57/B6 miceHepatocellular carcinomaGlypican-3B6 miceIntravenous infusionImmune responseTumor-specific cytotoxic T lymphocyte responsesCytotoxic T lymphocyte responsesBALB/c miceTumor necrosis factor alphaFirst preclinical evidenceLocal immune responseT lymphocyte responsesLimited treatment optionsDurable tumor regressionNecrosis factor alphaAnti-HCC effectsCultured HCC cellsCTL responsesLymphocyte responsesPreclinical evidenceAntibody therapyMost HCC tissuesHigh morbidityTreatment options